Intravacc and Therapyx jointly develop the world’s first prophylactic gonorrhea vaccine Bilthoven, The Netherlands, 25 August 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, has partnered with American, Buffalo, NY, based Therapyx,…
- Gonorrhea is the second most common bacterial infectious disease worldwide
- Vaccine based on IL12 in combination with intravacc’s gonorrhea OMV targeting mucosal immunization
- Induce an adaptive immune response for long term protection against the gonorrhea bacteria
- Mucosal vaccine platforms offer a broader perspective also for respiratory virus vaccines, such as Covid-19 and influenza